How semaglutide tablets work: the mechanism of action explained

Why getting semaglutide into the bloodstream through the stomach is harder than it sounds

Picture this: you've just read about the Wegovy tablet and your first thought is reasonable scepticism. GLP-1 medicines have always been injections, because peptide molecules (strings of amino acids) get dismantled by stomach acid and digestive enzymes before they can do anything useful. So how does an oral version work?

The answer is SNAC: sodium N-[8-(2-hydroxybenzoyl)amino]caprylate, a fatty-acid salt co-formulated with semaglutide in every tablet. When the tablet dissolves on an empty stomach, SNAC temporarily raises the pH directly around the tablet, creating a micro-environment that's slightly less acidic. That local shift protects semaglutide from enzymatic breakdown and, crucially, allows it to pass through the stomach lining into the bloodstream via transcellular absorption. The molecule doesn't travel through the intestine in the usual way; it slips across the gastric mucosa within a tight time window.

That window is why the dosing ritual matters so precisely. Any food, coffee or even most medicines in the stomach before absorption disrupts the SNAC micro-environment. The tablet has to arrive into an empty chamber with only a small amount of plain water (around 120ml) to dissolve correctly. Waiting at least 30 minutes afterwards isn't arbitrary caution; it's the time needed for absorption to complete before anything else competes with it. The full detail on taking semaglutide tablets covers this step by step.

Bioavailability is lower than injection, which is why the maintenance dose is 25mg rather than the 2.4mg weekly injection equivalent, the body absorbs a smaller fraction, so the tablet dose is scaled accordingly. If you want to understand how semaglutide in tablet form compares to other formats before going further, that page sets out the key differences clearly. The mechanism of delivery is different; the mechanism of action once absorbed is the same.

What semaglutide actually does once it's in your system

Once semaglutide reaches the circulation, it binds to GLP-1 receptors scattered across several systems simultaneously. The effect isn't one thing, it's a cluster of overlapping signals that together shift how hungry you feel, how fast food moves through you, and how your body handles glucose.

In the hypothalamus, GLP-1 receptor activation dampens the brain's hunger signals, the constant low hum of appetite that drives snacking and portion sizes. People often describe a quietening of food noise rather than feeling sick. In the gut, gastric emptying slows: food stays in the stomach longer, so the physical sensation of fullness arrives sooner and lingers. In the pancreas, semaglutide stimulates insulin release in a glucose-dependent way, meaning it responds to rising blood sugar rather than triggering insulin release regardless of what you've eaten, which reduces the risk of hypoglycaemia in people without diabetes.

These three pathways reinforce each other. You eat less because you're less hungry. You stop earlier because you feel fuller. Blood sugar rises more gradually because food moves through more slowly, and the pancreatic response is better matched to actual intake. The overview of oral semaglutide sets out what these effects mean practically for people starting treatment.

According to NHS guidance on semaglutide, common effects during the early weeks include nausea, reduced appetite and changes in digestion, signs the mechanism is active, and typically most noticeable when the dose is first increased before settling down.

The dose ladder and what it tells you about the mechanism

The Wegovy tablet schedule starts at 1.5mg daily and climbs through 4mg and 9mg to the 25mg maintenance dose, spending at least a month at each level. If that progression seems slow, it reflects something real about GLP-1 receptor agonism: flooding the receptors too quickly produces intense gastrointestinal side effects. The gradual escalation lets the gut adapt to slowed gastric emptying and the brain recalibrate to lower appetite signals.

Patients established on the 2.4mg weekly injection may move directly to the 25mg tablet, subject to clinical assessment, because the receptor-level effect is equivalent, even though the delivery route and absolute dose look very different. A prescriber makes that call.

The phase 3 OASIS 4 trial (307 adults, 64 weeks, published alongside the MHRA's June 2026 approval) reported around 13.6% average weight loss versus approximately 2.4% for placebo. Among participants who adhered fully throughout the trial, average loss reached around 17%, a figure worth noting alongside the wider average, since real-world adherence to the morning ritual varies. The dose escalation pathway also includes a step at semaglutide 7mg tablets, which our pharmacy page covers in detail for anyone who wants to understand that stage before starting. If you're weighing up the tablet against the injection, our comparison of the pill alternative to the weekly pen covers the practical differences.

Thinking about payday, a Monday start date or a holiday coming up? Starting dates are worth discussing at your consultation, since dose timing and the morning ritual are easier to bed in when your week has some routine around them.

What this means if you're considering the Wegovy tablet

The mechanism of action is the same as the injection, GLP-1 receptor agonism. The difference is purely the delivery system, and that delivery system places real demands on how you take it. Understanding the SNAC absorption window isn't a technicality; it's the difference between the tablet working as tested and underperforming because something disrupted absorption.

Wegovy tablets are a prescription-only medicine, licensed in the UK for adults with a BMI of 30 or above, or 27 and above alongside a weight-related health condition. Lower thresholds apply for some ethnic backgrounds under UK guidance. Suitability depends on a prescriber's full assessment, your health history, any other medicines you take, and whether the morning-dosing requirement is realistic for your life. The free consultation at nume is reviewed the same day by a GPhC-registered Independent Prescriber. A real clinician reads your answers.

If you'd like more background before booking, the weight-loss treatment overview covers the full range of options currently available through a UK-regulated private pharmacy. You can also read more about our clinical team and the oversight behind every prescription. When you're ready, start your free consultation and a prescriber will take it from there.